rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Sharon Mates

Director

Company insider

Files Form 4 as: Director, Seaport Therapeutics; Director, Benitec Biopharma; Chairman and CEO, Intra-Cellular Therapies.

Every Form 4 they filed

In numbers

Trades disclosed
254
Buys
0
Sells
47
Bought
$0
Sold
$83.6M
Companies
3
Companies where not an officer
2
First trade
30 Jun 2014
Last trade
30 Apr 2026
Last filed
4 May 2026

Companies traded

Where they are an officer
Intra-Cellular TherapiesDirector, Officer · last 2 Apr 20250 buys · 47 sells
Everywhere else they filed: board seats, 10% stakes, other companies
SPTX Seaport TherapeuticsDirector · Biotechnology · last 30 Apr 20260 buys · 0 sells
BNTC Benitec BiopharmaDirector · Biotechnology · last 22 Jan 20260 buys · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
30 Apr 2026filed 4 May 2026SPTX Seaport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—49,033 at $0.00filing
30 Apr 2026filed 4 May 2026SPTX Seaport Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—49,033 at $0.00filing
22 Jan 2026filed 26 Jan 2026BNTC Benitec Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—31,500 at $0.00filing
22 Jan 2026filed 26 Jan 2026BNTC Benitec Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—31,500 at $0.00filing
1 Dec 2025filed 3 Dec 2025BNTC Benitec Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—3,500 at $0.00filing
5 Nov 2025filed 7 Nov 2025BNTC Benitec Biopharmaoption or derivative · BiotechnologySEC FORM 4 Code A—28,517 at $0.00filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—86,003filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—135,399filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—138,473filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—66,886filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—53,471filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—50,167filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—40,713filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—69,940filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—121,212filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code A—40,712 at $0.00filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—40,712filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code A—34,970 at $0.00filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular Therapiesoption or derivativeSEC FORM 4 Code D—34,970filing
2 Apr 2025filed 2 Apr 2025Intra-Cellular TherapiesSEC FORM 4 Code D$124.8M945,235 at $132.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed47

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.